119 related articles for article (PubMed ID: 7585536)
1. Antiproliferative and angiostatic activity of suramin analogues.
Firsching A; Nickel P; Mora P; Allolio B
Cancer Res; 1995 Nov; 55(21):4957-61. PubMed ID: 7585536
[TBL] [Abstract][Full Text] [Related]
2. Angiostatic effects of suramin analogs in vitro.
Firsching-Hauck A; Nickel P; Yahya C; Wandt C; Kulik R; Simon N; Zink M; Nehls V; Allolio B
Anticancer Drugs; 2000 Feb; 11(2):69-77. PubMed ID: 10789588
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of heparanase activity and heparanase-induced angiogenesis by suramin analogues.
Marchetti D; Reiland J; Erwin B; Roy M
Int J Cancer; 2003 Mar; 104(2):167-74. PubMed ID: 12569571
[TBL] [Abstract][Full Text] [Related]
4. Antiproliferative activity in vitro of side-chain analogues of calcitriol against various human normal and cancer cell lines.
Opolski A; Wietrzyk J; Chrobak A; Marcinkowska E; Wojdat E; Kutner A; Radzikowski C
Anticancer Res; 1999; 19(6B):5217-22. PubMed ID: 10697538
[TBL] [Abstract][Full Text] [Related]
5. Antiangiogenic and antiproliferative activity of suramin analogues.
Gagliardi AR; Kassack M; Kreimeyer A; Muller G; Nickel P; Collins DC
Cancer Chemother Pharmacol; 1998; 41(2):117-24. PubMed ID: 9443624
[TBL] [Abstract][Full Text] [Related]
6. Structure-activity studies on suramin analogues as inhibitors of NAD+-dependent histone deacetylases (sirtuins).
Trapp J; Meier R; Hongwiset D; Kassack MU; Sippl W; Jung M
ChemMedChem; 2007 Oct; 2(10):1419-31. PubMed ID: 17628866
[TBL] [Abstract][Full Text] [Related]
7. Structure-activity relationships of antineoplastic ring-substituted ether phospholipid derivatives.
Papazafiri P; Avlonitis N; Angelou P; Calogeropoulou T; Koufaki M; Scoulica E; Fragiadaki I
Cancer Chemother Pharmacol; 2005 Sep; 56(3):261-70. PubMed ID: 15856232
[TBL] [Abstract][Full Text] [Related]
8. Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy.
Drevs J; Fakler J; Eisele S; Medinger M; Bing G; Esser N; Marmé D; Unger C
Anticancer Res; 2004; 24(3a):1759-63. PubMed ID: 15274352
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and anticancer activity of nordihydroguaiaretic acid (NDGA) and analogues.
McDonald RW; Bunjobpon W; Liu T; Fessler S; Pardo OE; Freer IK; Glaser M; Seckl MJ; Robins DJ
Anticancer Drug Des; 2001 Dec; 16(6):261-70. PubMed ID: 12375879
[TBL] [Abstract][Full Text] [Related]
10. Different ways to antiangiogenesis by angiostatin and suramin, and quantitation of angiostatin-induced antiangiogenesis.
Bahramsoltani M; Plendl J
APMIS; 2007 Jan; 115(1):30-46. PubMed ID: 17223849
[TBL] [Abstract][Full Text] [Related]
11. Antiproliferative activity of colchicine analogues on MDR-positive and MDR-negative human cancer cell lines.
De Vincenzo R; Scambia G; Ferlini C; Distefano M; Filippini P; Riva A; Bombardelli E; Pocar D; Gelmi ML; Benedetti Panici P; Mancuso S
Anticancer Drug Des; 1998 Jan; 13(1):19-33. PubMed ID: 9474240
[TBL] [Abstract][Full Text] [Related]
12. Novel oxadiazole analogues derived from ethacrynic acid: design, synthesis, and structure-activity relationships in inhibiting the activity of glutathione S-transferase P1-1 and cancer cell proliferation.
Yang X; Liu G; Li H; Zhang Y; Song D; Li C; Wang R; Liu B; Liang W; Jing Y; Zhao G
J Med Chem; 2010 Feb; 53(3):1015-22. PubMed ID: 20055416
[TBL] [Abstract][Full Text] [Related]
13. Suramin analogs inhibit human angiogenesis in vitro.
Meyers MO; Gagliardi AR; Flattmann GJ; Su JL; Wang YZ; Woltering EA
J Surg Res; 2000 Jun; 91(2):130-4. PubMed ID: 10839961
[TBL] [Abstract][Full Text] [Related]
14. Antitumour activity of suramin analogues in human tumour cell lines and primary cultures of tumour cells from patients.
Dhar S; Gullbo J; Csoka K; Eriksson E; Nilsson K; Nickel P; Larsson R; Nygren P
Eur J Cancer; 2000 Apr; 36(6):803-9. PubMed ID: 10762755
[TBL] [Abstract][Full Text] [Related]
15. 2-Substituted aminopyrido[2,3-d]pyrimidin-7(8H)-ones. structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity.
Klutchko SR; Hamby JM; Boschelli DH; Wu Z; Kraker AJ; Amar AM; Hartl BG; Shen C; Klohs WD; Steinkampf RW; Driscoll DL; Nelson JM; Elliott WL; Roberts BJ; Stoner CL; Vincent PW; Dykes DJ; Panek RL; Lu GH; Major TC; Dahring TK; Hallak H; Bradford LA; Showalter HD; Doherty AM
J Med Chem; 1998 Aug; 41(17):3276-92. PubMed ID: 9703473
[TBL] [Abstract][Full Text] [Related]
16. Suramin blocks binding of interleukin-4 to its receptors on human tumor cells and interleukin-4-induced mitogenic response.
Leland P; Obiri N; Aggarwal BB; Puri RK
Oncol Res; 1995; 7(5):227-35. PubMed ID: 8534928
[TBL] [Abstract][Full Text] [Related]
17. [The enhancement of the chemotherapeutic effects on human prostate cancer cell--the combination with the growth factor interaction inhibitor (suramin)].
Suzuki Y; Miwa Y; Akino H; Fujita T; Saikawa S; Kanimoto Y; Okada K
Hinyokika Kiyo; 1993 Dec; 39(12):1215-20. PubMed ID: 8285172
[TBL] [Abstract][Full Text] [Related]
18. Suramin is synergistic with vinblastine in human colonic tumor cell lines: effect of cell density and timing of drug delivery.
Frommel TO
Anticancer Res; 1997; 17(3C):2065-71. PubMed ID: 9216665
[TBL] [Abstract][Full Text] [Related]
19. Biased inhibition by a suramin analogue of A1-adenosine receptor/G protein coupling in fused receptor/G protein tandems: the A1-adenosine receptor is predominantly coupled to Goalpha in human brain.
Kudlacek O; Waldhoer M; Kassack MU; Nickel P; Salmi JI; Freissmuth M; Nanoff C
Naunyn Schmiedebergs Arch Pharmacol; 2002 Jan; 365(1):8-16. PubMed ID: 11862328
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and antiproliferative activity of unsaturated quinoline derivatives.
Montgomery GJ; McKeown P; McGown AT; Robins DJ
Anticancer Drug Des; 2000 Jun; 15(3):171-81. PubMed ID: 11049085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
